Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Silvy Laporte

Showing results (1-10 of 131) with videos related to

Pageof 14
Sort By:
Haematologica|July 2, 2002
Thromboprophylaxis in acute medical patients: need for an implementation strategyPatrick Mismetti, Silvy Laporte
Therapie|June 5, 2017
[False positive results or what's the probability that a significant P-value indicates a true effect?]Michel Cucherat, Silvy Laporte
Critical Care Medicine|January 20, 2010
Epidemiology of thrombotic risk factors: the difficulty in using clinical trials to develop a risk assessment modelSilvy Laporte, Patrick Mismetti
Presse Medicale (Paris, France : 1983)|February 6, 2007
[Meta-analyses or megatrials: same level of proof?]Patrick Mismetti, Michel Cucherat, Silvy Laporte
Therapie|April 16, 2016
Clinical research and methodology: What usage and what hierarchical order for secondary endpoints?Silvy Laporte, Marine Diviné, Danièle Girault, et al.
Pharmacological Research|March 12, 2017
Introductory letter to the special issue "Country in focus, pharmacology in France"Marie-Christine Perault-Pochat, Silvy Laporte
The New England Journal of Medicine|July 17, 2025
Apixaban for Cancer-Associated Venous Thromboembolism. ReplyIsabelle Mahé, Marc Carrier, Silvy Laporte
The Lancet. Haematology|March 6, 2026
Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated VTE - Authors' replyIsabelle Mahé, Céline Chapelle, Silvy Laporte
Archives of Internal Medicine|February 26, 2004
Thrombosis prophylaxis in cancer patients with a central venous catheterSilvy Laporte, Hervé Decousus, Patrick Mismetti
Revue Medicale Suisse|March 15, 2014
[New oral anticoagulants: pharmacological data to know for clinical practice]Xavier Delavenne, Silvy Laporte, Patrick Mismetti
Pageof 14

Showing results (1-10 of 131) with videos related to

Sort By:
Pageof 14
Haematologica|July 2, 2002
Thromboprophylaxis in acute medical patients: need for an implementation strategyPatrick Mismetti, Silvy Laporte
Therapie|June 5, 2017
[False positive results or what's the probability that a significant P-value indicates a true effect?]Michel Cucherat, Silvy Laporte
Critical Care Medicine|January 20, 2010
Epidemiology of thrombotic risk factors: the difficulty in using clinical trials to develop a risk assessment modelSilvy Laporte, Patrick Mismetti
Presse Medicale (Paris, France : 1983)|February 6, 2007
[Meta-analyses or megatrials: same level of proof?]Patrick Mismetti, Michel Cucherat, Silvy Laporte
Therapie|April 16, 2016
Clinical research and methodology: What usage and what hierarchical order for secondary endpoints?Silvy Laporte, Marine Diviné, Danièle Girault, et al.
Pharmacological Research|March 12, 2017
Introductory letter to the special issue "Country in focus, pharmacology in France"Marie-Christine Perault-Pochat, Silvy Laporte
The New England Journal of Medicine|July 17, 2025
Apixaban for Cancer-Associated Venous Thromboembolism. ReplyIsabelle Mahé, Marc Carrier, Silvy Laporte
The Lancet. Haematology|March 6, 2026
Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated VTE - Authors' replyIsabelle Mahé, Céline Chapelle, Silvy Laporte
Archives of Internal Medicine|February 26, 2004
Thrombosis prophylaxis in cancer patients with a central venous catheterSilvy Laporte, Hervé Decousus, Patrick Mismetti
Revue Medicale Suisse|March 15, 2014
[New oral anticoagulants: pharmacological data to know for clinical practice]Xavier Delavenne, Silvy Laporte, Patrick Mismetti
Pageof 14